De zilverprijs bereikte heeft dit jaar een recordhoogte van 54,48 Amerikaanse dollar per ounce. Voor 2025 verwachten ...

BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical introduced the results from an aggregated data analysis at the Vascular Interventional Advances (VIVA) conference, highlighting the Zilver ® PTX ® Drug ...

The FDA today approved Cook Medical's Zilver PTX stent. It is the first drug-eluting stent (DES) approved for the treatment of peripheral arterial disease (PAD) in the superficial femoral and proximal ...

Treating superficial femoral artery (SFA) disease remains challenging. Bypass surgery is associated with higher morbidity rates than endovascular therapies, such as percutaneous transluminal ...

Zilver PTX stenting would be superior to PTA alone in the treatment of patients with symptomatic femoropopliteal disease. Patients were randomized in a 1:1 fashion to either Zilver PTX stent or PTA.

Purpose: The benefit of using the Zilver PTX drug-eluting stent (DES) in superficial femoral artery (SFA) lesions has been demonstrated in multiple clinical studies. This prospective, multicenter ...

After more than a year in the works, Cook Medical’s Zilver PTX stent got a unanimous boost from the FDA’s Circulatory Systems Devices Panel, putting it on track for U.S. market clearance in the next ...

February 20, 2019—A correction to the 5-year data publication from Cook Medical's Zilver PTX randomized trial was issued in Circulation (2019;139:e42), revising a key figure and the stated mortality ...

LAS VEGAS--(BUSINESS WIRE)--Three-year data from the Zilver ® PTX ® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical demonstrate 70.7 percent ...

Bloomington, IN - Cook Medical's Zilver Vascular Stent system has received approval from Health Canada's Therapeutic Products Directorate for use treating symptomatic vascular disease of the iliac ...